How Pharma Teams Evaluate Biotech Companies for Partnerships and Acquisitions
Addressing how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations.
Partner Content How Pharma Teams Evaluate Biotech Companies for Partnerships and Acquisitions By Andrew Goldstein Aug 19, 2026 9:11am CMO Multimedia webcast Partner Content This podcast features a panel discussion from the 2026 Chief Medical Officer Summit 360°, with biotech CMOs and representatives from pharma companies. Together, they address how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations. This includes: How pharma companies analyze potential partnersWhat biotech companies can do to best partner with pharma How the CMO fits into various phases of transactionsAppreciating how different c-suite colleagues and direct reports experience these transactionsThe different pharma teams CMOs will interact withCommon challenges to partnerships and how to pre-empt themWhat happens after the acquisition To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.
CMO Multimedia webcast Partner Content
comments(0)
5-min edit window · permanent after that